Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06439693
What this trial is testing

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Who this might be right for
Breast Cancer FemaleBreast CancerBreast Cancer Metastatic+3 more
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Testing effectiveness (Phase 2)UnknownNCT03750396
What this trial is testing

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Who this might be right for
Breast CancerRecurrent Breast CancerStereotactic Body Radiotherapy+3 more
Gangnam Severance Hospital 110
Testing effectiveness (Phase 2)Ended earlyNCT01272141
What this trial is testing

Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerCancer of the Breast
Emory University 5
Not applicableStudy completedNCT04480814
What this trial is testing

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

Who this might be right for
Breast Cancer
Pharmassist Ltd 30
Testing effectiveness (Phase 2)Study completedNCT01147484
What this trial is testing

Foretinib in Patients With Recurrent/Metastatic Breast Cancer

Who this might be right for
Recurrent Breast Cancer
NCIC Clinical Trials Group 47
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Testing effectiveness (Phase 2)Study completedNCT01151046
What this trial is testing

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Who this might be right for
Her2 Negative Breast Cancer Patients
Merrimack Pharmaceuticals 118
Testing effectiveness (Phase 2)UnknownNCT04858997
What this trial is testing

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

Who this might be right for
Breast Neoplasms
Zhejiang Cancer Hospital 150
Testing effectiveness (Phase 2)Study completedNCT01381874
What this trial is testing

Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Who this might be right for
Metastatic ER+ Her2- Breast CancerPostmenopausal
Janssen Research & Development, LLC 297
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Not applicableNo Longer AvailableNCT01130259
What this trial is testing

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Who this might be right for
Breast Cancer
Sanofi
Testing effectiveness (Phase 2)Looking for participantsNCT05305924
What this trial is testing

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Who this might be right for
ER-Positive Breast CancerHER2-negative Breast Cancer
The Methodist Hospital Research Institute 28
Early research (Phase 1)WithdrawnNCT02567396
What this trial is testing

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Who this might be right for
Estrogen Receptor NegativeHead and Neck Squamous Cell CarcinomaHER2/Neu Negative+20 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Ended earlyNCT03566485
What this trial is testing

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Who this might be right for
Stage III Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer+4 more
Vanderbilt-Ingram Cancer Center 12
Large-scale testing (Phase 3)Not Yet RecruitingNCT07717450
What this trial is testing

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

Who this might be right for
Metastatic Invasive Breast Cancer
UNICANCER 370
Not applicableNot Yet RecruitingNCT06882499
What this trial is testing

Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

Who this might be right for
Breast Cancer, MetastaticMetastatic Breast Cancer
Peter MacCallum Cancer Centre, Australia 74
Not applicableUnknownNCT04247035
What this trial is testing

Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hellenic Society of Medical Oncology 300
Large-scale testing (Phase 3)Study completedNCT03096847
What this trial is testing

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 502
Next Page